Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
How Does Mounjaro Work? GIP + GLP-1 Mechanism for Type 2 Diabetes
articleMounjaro (tirzepatide) treats type 2 diabetes by activating two incretin receptors at once. Here is the organ-level physiology, the SURPASS-1 evidence behind its 2022 FDA approval, and how it compares to Ozempic in head-to-head trials.
Mounjaro (Tirzepatide) Dosage Chart for Type 2 Diabetes
guidesComplete Mounjaro (tirzepatide) dosage chart for type 2 diabetes. Covers the full 2.5 mg to 15 mg titration schedule, SURPASS-1 HbA1c reduction data, KwikPen injection guide, missed-dose rules, and dosing in special populations.